Journal: OncoImmunology

Article Title: CD169 identifies an activated CD8+T cell subset in regional lymph nodes that predicts favorable prognosis in colorectal cancer patients

doi: 10.1080/2162402x.2016.1177690

Figure Lengend Snippet: Figure 1. CD169+CD8+ T cells are selectively present in the regional LNs and decreased

Article Snippet: Frozen LN tissue sections were stained with sheep anti-human CD169 (R&D Systems, Minneapolis, MN, USA), mouse anti-human CD3 or mouse anti-human CD68 (Thermo Fisher Scientific, Waltham, MA, USA) and rabbit anti-human CD8 (Thermo Fisher Scientific), followed by specimen-paired immunofluorescence secondary antibodies (Life Technologies, Carlsbad, CA, USA).

Techniques:

Journal:

Article Title:

doi:

Figure Lengend Snippet: Soluble SIGLEC-1 is a surrogate for the surface expression of SIGLEC-1 on CD14 + monocytes. a Gating strategy for the delineation of CD14 + monocytes, following single-cell discrimination. Histograms depict the distribution of SIGLEC-1 expression on the surface of CD14 + monocytes obtained by flow cytometry in illustrative donors expressing low normal (blue), normal (green), high (orange) or very high (red) levels of SIGLEC-1. Dotted line represents the background expression of SIGLEC-1 in live lymphocytes, which are known not to express SIGLEC-1. b Scatter plot depicts the frequency (geometric mean ± 95% CI) of SIGLEC-1 expression on the surface of CD14 + monocytes in a discovery cohort (cohort 1) of healthy donors ( N = 24; black squares) and SLE patients ( N = 34; red triangles). P value was calculated using a two-tailed non-parametric Mann–Whitney test. c Correlation between SIGLEC-1 mean fluorescence intensity (MFI) on CD14 + monocytes obtained by flow cytometry and the corresponding sSIGLEC-1 concentration in the healthy control and SLE patient groups. P value was calculated by linear regression. Illustrative SIGLEC-1 low normal, normal, high and very high SLE patients shown in ( a ) are highlighted in ( b ) and ( c ). SIGLEC-1 sialic acid binding Ig-like lectin 1, sSIGLEC-1 soluble SIGLEC-1, SLE systemic lupus erythematosus

Article Snippet: Duplicate test plasma/serum samples diluted 1:10 in assay buffer (PBS, 0.05% Tween-20, 10% FCS) were incubated for 2 h at room temperature and then at 4 °C overnight in 96-well EIA/RIA plates (Corning) coated with 1 μg/ml mouse monoclonal anti-human SIGLEC-1 capture antibody (AB18619; Abcam).

Techniques: Expressing, Flow Cytometry, Two Tailed Test, MANN-WHITNEY, Fluorescence, Concentration Assay, Binding Assay

Journal: Oncotarget

Article Title: High CD204 + tumor-infiltrating macrophage density predicts a poor prognosis in patients with urothelial cell carcinoma of the bladder

doi:

Figure Lengend Snippet: A. Anti-α-SMA staining was used to distinguish intratumoral (INT) from stromal (ST) regions. B. Representative immunohistochemistry images of CD68 + Mφs, CD204 + Mφs, and CD169 + Mφs in human UCB tissues. The micrographs at higher magnification show stained INT (1) and ST (2) regions. Scale bar, 100 μm. C. The numbers of CD68 + Mφs, CD204 + Mφs, and CD169 + Mφs in the INT and ST regions of human UCB tissues. Cell numbers were calculated as the cell count per × 400 field. Data are expressed as means ± SEM.

Article Snippet: After overnight incubation at 4°C with antibodies against human α-SMA (1:500 dilution, Zhongshan Bio-Tech Co., Zhongshan, China), CD68 (1:500 dilution, Dako A/S, Glostrup, Copenhagen, Denmark), CD169 (1:200 dilution, R&D Systems, Minneapolis, MN, USA), CD204 (1:500, dilution, Transgenic, Kumamoto, Japan), or control antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA), sections were incubated with secondary antibodies conjugated to horseradish peroxidase (Envision + Dual Link Kit, DAKO, for mouse/rabbit antibodies; or R&D Systems for donkey anti-sheep secondary antibody) for 30 min.

Techniques: Staining, Immunohistochemistry, Cell Counting